These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15813916)

  • 1. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience.
    Yanada M; Suzuki M; Kawashima K; Kiyoi H; Kinoshita T; Emi N; Saito H; Naoe T
    Eur J Haematol; 2005 May; 74(5):418-23. PubMed ID: 15813916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.
    Arber DA; Stein AS; Carter NH; Ikle D; Forman SJ; Slovak ML
    Am J Clin Pathol; 2003 May; 119(5):672-80. PubMed ID: 12760285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of 572 adult acute leukemia patients in Shanghai according to WHO classification].
    Sino US Leukemia Cooperative Group of Shanghai
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):444-8. PubMed ID: 18072625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations.
    Bao L; Wang X; Ryder J; Ji M; Chen Y; Chen H; Sun H; Yang Y; Du X; Kerzic P; Gross SA; Yao L; Lv L; Fu H; Lin G; Irons RD
    Eur J Haematol; 2006 Jul; 77(1):35-45. PubMed ID: 16573742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia].
    Braham-Jmili N; Sendi-Senana H; Labiadh S; Ben Abdelali R; Ben Abdelaziz A; Khelif A; Saad A; Kortas M
    Ann Biol Clin (Paris); 2006; 64(5):457-65. PubMed ID: 17040877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
    Cortes JE; Talpaz M; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Rios MB; Shan J; Kantarjian HM
    Cancer; 2006 Mar; 106(6):1306-15. PubMed ID: 16463391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
    Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant and opportunistic leukemic clones: proposal for a pathogenesis-oriented classification in acute myeloid leukemia.
    Cucuianu A
    Med Hypotheses; 2005; 65(1):107-13. PubMed ID: 15893127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden.
    Aström M; Bodin L; Nilsson I; Tidefelt U
    Br J Cancer; 2000 Apr; 82(8):1387-92. PubMed ID: 10780515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
    Roberson JR; Onciu M; Pounds S; Rubnitz JE; Pui CH; Razzouk BI
    Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.